List view / Grid view
A new study reveals that blocking the enzyme ST6Gal-I reduces toxic plaque buildup in Alzheimer’s disease by suppressing BACE1 expression - highlighting a new target for future treatment strategies.
Researchers at POSTECH have developed a new 3D brain model that closely mimics the structure and function of human brain tissue – marking a major advance in early disease detection.
Mayo Clinic researchers have created the world’s first biobank of human salivary gland tissue-organoids, offering a resource for developing regenerative therapies to treat chronic dry mouth.
Porosome Therapeutics has made a groundbreaking discovery in Alzheimer’s research by targeting the disease’s molecular causes, focusing on restoring secretory and metabolic functions. This approach could not only slow progression but potentially reverse early-stage pathology.
Promising preliminary research reveals a novel vaccine targeting an Alzheimer’s disease-related protein successfully eliminated toxic cells in mice afflicted with the condition.
Central nervous system (CNS) research is making breakthroughs with innovative therapies and next-generation technologies. Researchers are now able to use human tissue to identify relevant novel drug targets and biomarkers for a broad range of CNS diseases including schizophrenia, Alzheimer’s disease and Parkinson’s disease. As our understanding of the brain…
Researchers have discovered that oligodendrocyte-lineage cells transfer cell material to neurons in a mouse brain. They have provided the first evidence of coordinated nuclear interaction between these cells and neurons.
The activity of enzyme ATE1, as seen by US researchers, flags misfolded proteins for destruction and is enhanced by binding iron-sulphur clusters.
Sphingosine-1 phosphate was found to regulate blood glow in cerebral blood vessels in mice, presenting a potential therapeutic target.
Researchers have uncovered a signalling pathway associated with glutamatergic synapse degeneration in the brains of mice with Alzheimer’s.
A drug called CMS121 given to mice with Alzheimer's-like disease treated their memory loss, allowing them to perform the same as healthy control mice in tests.
A new compound named L1 has demonstrated success in mice, by reducing neuroinflammation and decreasing the levels of amyloid plaques, showing potential as an Alzheimer's treatment.
Novel promoters based on those in the herpes viruses, enabled delivery of larger genes and increased the period they were active in the nervous system.
Drug Target Review discusses how NETSseq, a novel profiling technology, is bringing new insights to neurodegenerative and psychiatric diseases.
A group of researchers has synthesised a new class of ligands which bind with high affinity to imidazoline I2 receptors, a drug target for Alzheimer's disease.
